The reduction in adjusted EPS primarily reflected the impact from lower sales of COVID-19 solutions low margin Xevudy and pandemic adjuvant, higher interest costs and a higher effective tax rate compared to Q4 2021. Total operating profit from continuing operations was GBP 1,868 million compared with GBP 492 million in Q4 2021. Cash generated from operations attributable to continuing operations for the quarter was GBP 2,101 million. Profit after taxation from discontinued operations amounted to GBP 10,700 million. CEO Emma Walmsley said: "2022 was a landmark year for GSK delivering the step change in performance we committed to, driven by strong growth in specialty medicines and vaccines, including record sales for Shingrix. We enter 2023 with good momentum, underpinning confidence in our ambitious sales and profit outlooks for 2026. At the sametime, we continue to build a stronger portfolio and pipeline based on infectious diseases and the science of the immune system, including our potential new RSV vaccine. This momentum, together with further targeted business development, means GSK will also be in a strong position to deliver growth from 2026 onwards."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on GSK:
- JMP Securities says older-adult update continues to look encouraging for CureVac
- CureVac announces data in older adults from COVID-19, flu mRNA vaccines
- GSK’s belimumab granted orphan designation as treatment of systemic sclerosis
- Moderna price target raised to $111 from $102 at SVB Securities
- Regenxbio names Curran Simpson as COO